Homology modeling and ligand docking of Mitogen-activated protein kinase-activated protein kinase 5 (MK5)

Theoretical Biology and Medical Modelling

Volumn 10, Issue 1, 2013, Pages

  Lindin, Inger ^a   Wuxiuer, Yimingjiang ^a   Kufareva, Irina ^b   Abagyan, Ruben ^b   Moens, Ugo ^a   Sylte, Ingebrigt ^a   Ravna, Aina Westrheim ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Docking; Homology modeling; ICM program package; MAPKAPK5; Molecular dynamics; PRAK

Indexed keywords

VERTEBRATA;

ADENOSINE TRIPHOSPHATE; LIGAND; MAP KINASE ACTIVATED KINASE 5; MAP-KINASE-ACTIVATED KINASE 5; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; IC 50; METABOLISM; MOLECULAR DOCKING; MOLECULAR GENETICS; RECEIVER OPERATING CHARACTERISTIC; STATIC ELECTRICITY; STRUCTURAL HOMOLOGY; X RAY CRYSTALLOGRAPHY;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HUMANS; INHIBITORY CONCENTRATION 50; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; ROC CURVE; STATIC ELECTRICITY; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 84883682129     PISSN: None     EISSN: 17424682     Source Type: Journal    
DOI: 10.1186/1742-4682-10-56     Document Type: Article

References (63)

1. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Cargnello M, Roux PP, Microbiol Mol Biol Rev 2011 75 1 50 83 10.1128/MMBR.00031-10 21372320
2. MAPKAP kinases-MKs-two's company, three's a crowd. Gaestel M, Nat Rev Mol Cell Biol 2006 7 2 120 30 10.1038/nrm1834 16421520
3. Physiological roles of mitogen-activated-protein-kinase-activated p38-regulated/activated protein kinase. Kostenko S, et al. World J Biol Chem 2011 2 5 73 89 10.4331/wjbc.v2.i5.73 21666810
4. MAPKAPK5, a novel mitogen-activated protein kinase (MAPK)-activated protein kinase, is a substrate of the extracellular-regulated kinase (ERK) and p38 kinase. Ni H, et al. Biochem Biophys Res Commun 1998 243 2 492 6 10.1006/bbrc.1998.8135 9480836
5. PRAK, a novel protein kinase regulated by the p38 MAP kinase. New L, et al. EMBO J 1998 17 12 3372 84 10.1093/emboj/17.12.3372 9628874
6. Does MK5 reconcile classical and atypical MAP kinases? Perander M, Keyse SM, Seternes OM, Front Biosci 2008 13 4617 24 18508533
7. The transcriptional regulation and cell-specific expression of the MAPK-activated protein kinase MK5. Gerits N, et al. Cell Mol Biol Lett 2009 14 4 548 74 10.2478/s11658-009-0020-6 19484198
8. Both binding and activation of p38 mitogen-activated protein kinase (MAPK) play essential roles in regulation of the nucleocytoplasmic distribution of MAPK-activated protein kinase 5 by cellular stress. Seternes OM, et al. Mol Cell Biol 2002 22 20 6931 45 10.1128/MCB.22.20.6931-6945.2002 12242275
9. Regulation of PRAK subcellular location by p38 MAP kinases. New L, Jiang Y, Han J, Mol Biol Cell 2003 14 6 2603 16 10.1091/mbc.E02-08-0538 12808055
10. Scaffolding by ERK3 regulates MK5 in development. Schumacher S, et al. EMBO J 2004 23 24 4770 9 10.1038/sj.emboj.7600467 15538386
11. Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5. Kant S, et al. J Biol Chem 2006 281 46 35511 9 10.1074/jbc.M606693200 16973613
12. Modulation of F-actin rearrangement by the cyclic AMP/cAMP-dependent protein kinase (PKA) pathway is mediated by MAPK-activated protein kinase 5 and requires PKA-induced nuclear export of MK5. Gerits N, et al. J Biol Chem 2007 282 51 37232 43 10.1074/jbc.M704873200 17947239
13. Activation loop phosphorylation of the atypical MAP kinases ERK3 and ERK4 is required for binding, activation and cytoplasmic relocalization of MK5. Deleris P, et al. J Cell Physiol 2008 217 3 778 88 10.1002/jcp.21560 18720373
14. A functional link between the human cell cycle-regulatory phosphatase Cdc14A and the atypical mitogen-activated kinase Erk3. Hansen CA, Bartek J, Jensen S, Cell Cycle 2008 7 3 325 34 10.4161/cc.7.3.5354 18235225
15. Mechanisms regulating the nuclear translocation of p38 MAP kinase. Gong X, et al. J Cell Biochem 2010 110 6 1420 9 10.1002/jcb.22675 20506250
16. Serine residue 115 of MAPK-activated protein kinase MK5 is crucial for its PKA-regulated nuclear export and biological function. Kostenko S, et al. Cell Mol Life Sci 2011 68 5 847 62 10.1007/s00018-010-0496-2 20734105
17. Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: menage a trois or menage a quatre? Shiryaev A, Moens U, Cell Signal 2010 22 8 1185 92 10.1016/j.cellsig.2010.03.002 20227494
18. 14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-actin polymerization. Tak H, et al. Cell Signal 2007 19 11 2379 87 10.1016/j.cellsig.2007.07.016 17728103
19. PKA-induced F-actin rearrangement requires phosphorylation of Hsp27 by the MAPKAP kinase MK5. Kostenko S, Johannessen M, Moens U, Cell Signal 2009 21 5 712 8 10.1016/j.cellsig.2009.01.009 19166925
20. Absence of a human DnaJ protein hTid-1S correlates with aberrant actin cytoskeleton organization in lesional psoriatic skin. Choi JH, et al. The Journal of biological chemistry 2012 287 31 25954 63 10.1074/jbc.M111.313809 22692211
21. The p38 pathway provides negative feedback for Ras proliferative signaling. Chen G, et al. J Biol Chem 2000 275 50 38973 80 10.1074/jbc. M002856200 10978313
22. Determinants that control the distinct subcellular localization of p38alpha-PRAK and p38beta-PRAK complexes. Li Q, et al. J Biol Chem 2008 283 16 11014 23 10.1074/jbc.M709682200 18268017
23. PRAK is essential for ras-induced senescence and tumor suppression. Sun P, et al. Cell 2007 128 2 295 308 10.1016/j.cell.2006.11.050 17254968
24. The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis. Kress TR, et al. Mol Cell 2011 41 4 445 57 10.1016/j.molcel.2011.01.023 21329882
25. Rapid turnover of extracellular signal-regulated kinase 3 by the ubiquitin-proteasome pathway defines a novel paradigm of mitogen-activated protein kinase regulation during cellular differentiation. Coulombe P, et al. Mol Cell Biol 2003 23 13 4542 58 10.1128/MCB.23.13.4542-4558.2003 12808096
26. Nuclear export of ERK3 by a CRM1-dependent mechanism regulates its inhibitory action on cell cycle progression. Julien C, Coulombe P, Meloche S, J Biol Chem 2003 278 43 42615 24 10.1074/jbc.M302724200 12915405
27. IGF2BP1 promotes cell migration by regulating MK5 and PTEN signaling. Stohr N, et al. Genes Dev 2012 26 2 176 89 10.1101/gad.177642.111 22279049
28. PRAK suppresses oncogenic ras-induced hematopoietic cancer development by antagonizing the JNK pathway. Yoshizuka N, et al. Mol Cancer Res 2012 10 6 810 20 10.1158/1541-7786.MCR-11-0576 22665523
29. A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis. Yoshizuka N, et al. Mol Cell Biol 2012 32 3 606 18 10.1128/MCB.06301-11 22124154
30. Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1. Zheng M, et al. Nat Cell Biol 2011 13 3 263 72 10.1038/ncb2168 21336308
31. Transgenic mice expressing constitutive active MAPKAPK5 display gender-dependent differences in exploration and activity. Gerits N, Van Belle W, Moens U, Behav Brain Funct 2007 3 58 10.1186/1744-9081-3-58 17997833
32. T-Coffee: A novel method for fast and accurate multiple sequence alignment. Notredame C, Higgins DG, Heringa J, J Mol Biol 2000 302 1 205 17 10.1006/jmbi.2000.4042 10964570
33. Tcoffee@igs: A web server for computing, evaluating and combining multiple sequence alignments. Poirot O, O'Toole E, Notredame C, Nucleic Acids Res 2003 31 13 3503 6 10.1093/nar/gkg522 12824354
34. UniProt: the Universal Protein knowledgebase. Apweiler R, et al. Nucleic Acids Res 2004 32 9 115 10.1093/nar/gng157
35. The Protein Data Bank. Berman HM, et al. Nucleic Acids Res 2000 28 1 235 42 10.1093/nar/28.1.235 10592235
36. Basic local alignment search tool. Altschul SF, et al. J Mol Biol 1990 215 3 403 10 2231712
37. The diterpenoid alkaloid noroxoaconitine is a Mapkap kinase 5 (MK5/PRAK) inhibitor. Kostenko S, et al. Cellular and molecular life sciences: CMLS 2011 68 2 289 301 10.1007/s00018-010-0452-1 20640477
38. ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. Abagyan R, Totrov M, et al. Journal of Computational Chemistry 1994 15 5 488 506 10.1002/jcc.540150503
39. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. Abagyan R, Totrov M, J Mol Biol 1994 235 3 983 1002 10.1006/jmbi.1994.1052 8289329
40. PROCHECK: a program to check the stereochemical quality of protein structures. Laskowski RA, et al. Journal of Applied Crystallography 1993 26 2 283 291 10.1107/S0021889892009944
41. Errors in protein structures. Hooft RW, et al. Nature 1996 381 6580 272 8692262
42. Verification of protein structures: patterns of nonbonded atomic interactions. Colovos C, Yeates TO, Protein Sci 1993 2 9 1511 9 10.1002/pro.5560020916 8401235
43. a molecular modeling and drug design program. Vriend G, WHAT IF, J Mol Graph 1990 8 1 52 6 29 10.1016/0263-7855(90)80070-V 2268628
44. DaliLite workbench for protein structure comparison. Holm L, Park J, Bioinformatics 2000 16 6 566 7 10.1093/bioinformatics/16.6.566 10980157
45. Pocketome via comprehensive identification and classification of ligand binding envelopes. An J, Totrov M, Abagyan R, Mol Cell Proteomics 2005 4 6 752 61 10.1074/mcp.M400159-MCP200 15757999
46. Better decisions through science. Swets JA, Dawes RM, Monahan J, Sci Am 2000 283 4 82 7 10.1038/scientificamerican1000-82 11011389
47. An introduction to ROC analysis. Fawcett T, Pattern Recognition Letters 2006 27 8 861 874 10.1016/j.patrec.2005.10.010
48. Maestro, Schrödinger: LLC New York: NY 2010 20588672
49. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae. Jorgensen JH, et al. Journal of clinical microbiology 1996 34 11 2679 84 8897164
50. Nosé-Hoover chains: The canonical ensemble via continuous dynamics. Martyna GJK ML, Tuckerman M, Journal of Chemical Physics 1992 97 4 9
51. Constant pressure molecular dynamics algorithms. Martyna GJDJTKML, Journal of Chemical Physics 1994 101 5 13
52. A smooth particle mesh Ewald method. Essmann UPL, Berkowitz ML, Darden T, Lee H, Pedersen LG, Journal of Chemical Physics 1995 103 19 17
53. A Multiple-Time-Step Molecular Dynamics Algorithm for Macromolecules. Humphreys DDFRA, Berne BJ, Journal of Physical Chemistry 1994 98 27 6885 6892 10.1021/j100078a035
54. Molecular basis of MAPK-activated protein kinase 2:p38 assembly. White A, et al. Proc Natl Acad Sci U S A 2007 104 15 6353 8 10.1073/pnas.0701679104 17395714
55. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Revesz L, et al. Part II. Bioorg Med Chem Lett 2010 20 15 4719 23 10.1016/j.bmcl.2010.04.023
56. High-resolution crystal structure of human Mapkap kinase 3 in complex with a high affinity ligand. Cheng R, et al. Protein Sci 2010 19 1 168 73 19937655
57. Structural basis for a high affinity inhibitor bound to protein kinase MK2. Hillig RC, et al. J Mol Biol 2007 369 3 735 45 10.1016/j.jmb.2007.03.004 17449059
58. The conformational plasticity of protein kinases. Huse M, Kuriyan J, Cell 2002 109 3 275 82 10.1016/S0092-8674(02)00741-9 12015977
59. High-performance drug discovery: computational screening by combining docking and molecular dynamics simulations. Okimoto N, et al. PLoS computational biology 2009 5 10 1000528 10.1371/journal.pcbi.1000528 19816553
60. Rational design of inhibitors that bind to inactive kinase conformations. Liu Y, Gray NS, Nat Chem Biol 2006 2 7 358 64 10.1038/nchembio799 16783341
61. Targeting cancer with small molecule kinase inhibitors. Zhang J, Yang PL, Gray NS, Nature reviews. Cancer 2009 9 1 28 39 19104514
62. Developing irreversible inhibitors of the protein kinase cysteinome. Liu Q, et al. Chemistry & biology 2013 20 2 146 59 10.1016/j.chembiol.2012.12. 006 24052895
63. Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5. Kostenko S, Dumitriu G, Moens U, J Mol Signal 2012 7 1 9 10.1186/1750-2187-7-9 22800433